September 19, 2007 - For patients with equivocal or discordant findings on myocardial perfusion imaging, CT angiography (CTA) can unmask false-negative and false-positive results, according to Regina S. Druz, M.D., North Shore University Hospital in Manhasset, N.Y., told attendees at the American Society of Nuclear Cardiology meeting.

September 19, 2007 - With better quality sound, reproducibility potential for computer analysis, file-sharing and verification, the MP3 player could be used in place of a traditional stethoscope, reported Neil Skjodt, the Department of Medicine at the University of Alberta, Canada, at the annual Congress of the European Respiratory Society (ERS) in Stockholm, Sweden.

September 19, 2007 - Risk stratification using single-photon emission computed tomography (SPECT) led to shorter stays and fewer readmissions for hospitalized heart attack patients, according to a preliminary study presented by James Spalding, PharmD, at the American Society of Nuclear Cardiology meeting, held in San Diego, CA, from September 6 – 9.

The researchers found that stress SPECT was associated with significant reductions in:

September 18, 2007- With PET-guided lead placement, cardiac resynchronization therapy (CRT) can achieve significant clinical improvement in patients with severe ischemic heart failure, even in the presence of extensive scarring, reported investigators at the American Society of Nuclear Cardiology meeting, held in San Diego, CA, from September 6 – 9.

September 18, 2007 - Angiotech Pharmaceuticals Inc. announced that it reached a favorable agreement with Johnson & Johnson’s subsidiary, Conor Medsystems ("Conor") to settle all outstanding patent litigation with respect to Conor's CoStar paclitaxel stent.

"With this agreement now in place, Angiotech expects that the resources required to defend and enforce our intellectual property should decrease," said Dr. William Hunter, president and CEO of Angiotech.

September 18, 2007 - Baseline data from the largest study of U.S.-based heart failure (HF) patients in the outpatient setting demonstrate significant gaps and variation in medical care, particularly for women and the elderly, according to findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) study.

The study, sponsored by Medtronic Inc., was presented in a poster session at the Heart Failure Society of America Annual Scientific Meeting.

September 18, 2007 - The DuraHeart Left Ventricular Assist System (LVAS) reported a survival rate of 77 percent for all patients at 1 and 2 years, according to Aly El-Banayosy, M.D., from the Heart Center Nordrhein-Westfalen in Bad Oeynhausen, Germany, who presented a summary of the results from the European Clinical Trial at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland.

September 18, 2007 – CardioDynamics, an impedance cardiography (ICG) technology developer, announced plans to accelerate the its return to profitability capitalizing on the proceeds from the $8 million sale of Vermed, providing for strategic investments in revenue growth initiatives and expense reductions, including a 10 percent reduction in executive salaries.

September 18, 2007 - Vasogen Inc. announced plans for a confirmatory study of its Celacade technology for the treatment of patients with NYHA Class II heart failure, in order to support an application for regulatory approval in the U.S.

September 18, 2007 - Forty-one U.S. hospitals have been named 2007 Leapfrog Top Hospitals, based on results from the Leapfrog Hospital Quality and Safety Survey, a rating system that provides an up-to-the-minute assessment of a hospital's quality and safety.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now